STING-mediated cancer immunotherapy: emerging modalities and beyond.

Authors

Ramesha Hanumanthappa, Nandakumar Dalavaikodihalli Nanjaiah, Sudhir H Ranganath

Published in

Trends in pharmacological sciences. Jul 25, 2026. Epub Jul 25, 2026.

Abstract

The clinical translation of stimulator of interferon genes (STING)agonist-based cancer immunotherapy is limited by uncontrolled and sustained STING activation, which leads to immune exhaustion and systemic toxicity. In this forum, we critically analyze recent advances, including stimuli-responsive, biomimetic, pulsatile, intracellular-triggered release, and synergistic systems that enable precise spatiotemporal STING activation, as well as associated gaps in clinical translation. Finally, we present futuristic perspectives on next-generation STING-based cancer immunotherapy strategies.

PMID:
42502043
Bibliographic data and abstract were imported from PubMed on 26 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.